Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Androgenic Alopecia Overview 7 Therapeutics Development 8 Pipeline Products for Androgenic Alopecia - Overview 8 Androgenic Alopecia - Therapeutics under Development by Companies 9 Androgenic Alopecia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Androgenic Alopecia - Products under Development by Companies 13 Androgenic Alopecia - Companies Involved in Therapeutics Development 14 Aclaris Therapeutics Inc 14 Allergan Plc 15 Almirall SA 16 BiologicsMD Inc 17 Dong-A Socio Holdings Co Ltd 18 Histogen Inc 19 RepliCel Life Sciences Inc 20 RiverTown Therapeutics Inc 21 Samumed LLC 22 Sucampo Pharmaceuticals Inc 23 SWITCH Biotech LLC 24 Androgenic Alopecia - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 (cyclosporine A + minoxidil + RT-175) - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 bimatoprost - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 BMD-1341 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 BRM-421 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 CB-0301 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 finasteride - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 finasteride - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 HGEN-001 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 RCH-01 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 RK-023 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 setipiprant - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 SM-04554 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecule for Androgenic Alopecia - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Androgenic Alopecia - Dormant Projects 58 Androgenic Alopecia - Discontinued Products 59 Androgenic Alopecia - Product Development Milestones 60 Featured News & Press Releases 60 Oct 25, 2016: Samumed Successfully Completes a Phase II Androgenetic Alopecia Biopsy Trial Studying Regeneration of Hair Follicles 60 Sep 26, 2016: RepliCel Provides Update on Shiseido License and Co-Development for RCH-01 60 Jul 21, 2016: RepliCel Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan 61 Mar 07, 2016: Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia Trial 62 Feb 24, 2016: Cassiopea attains clinical endpoints in Breezula alopecia proof of concept trial 62 Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia 63 Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient 64 Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research 64 Dec 22, 2014: Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 65 Oct 09, 2014: RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum 66 May 20, 2014: RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness 66 Feb 27, 2014: RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine 67 Jan 13, 2014: RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology 67 Dec 19, 2013: RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness 67 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70

List of Tables Number of Products under Development for Androgenic Alopecia, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Androgenic Alopecia - Pipeline by Aclaris Therapeutics Inc, H2 2016 14 Androgenic Alopecia - Pipeline by Allergan Plc, H2 2016 15 Androgenic Alopecia - Pipeline by Almirall SA, H2 2016 16 Androgenic Alopecia - Pipeline by BiologicsMD Inc, H2 2016 17 Androgenic Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 18 Androgenic Alopecia - Pipeline by Histogen Inc, H2 2016 19 Androgenic Alopecia - Pipeline by RepliCel Life Sciences Inc, H2 2016 20 Androgenic Alopecia - Pipeline by RiverTown Therapeutics Inc, H2 2016 21 Androgenic Alopecia - Pipeline by Samumed LLC, H2 2016 22 Androgenic Alopecia - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016 23 Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Assessment by Combination Products, H2 2016 26 Number of Products by Stage and Target, H2 2016 28 Number of Products by Stage and Mechanism of Action, H2 2016 30 Number of Products by Stage and Route of Administration, H2 2016 32 Number of Products by Stage and Molecule Type, H2 2016 34 Androgenic Alopecia - Dormant Projects, H2 2016 58 Androgenic Alopecia - Discontinued Products, H2 2016 59 List of Figures Number of Products under Development for Androgenic Alopecia, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 12 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Targets, H2 2016 27 Number of Products by Stage and Targets, H2 2016 27 Number of Products by Top 10 Mechanism of Actions, H2 2016 29 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29 Number of Products by Routes of Administration, H2 2016 31 Number of Products by Stage and Routes of Administration, H2 2016 31 Number of Products by Molecule Types, H2 2016 33 Number of Products by Stage and Molecule Types, H2 2016 33

Aclaris Therapeutics Inc Allergan Plc Almirall SA BiologicsMD Inc Dong-A Socio Holdings Co Ltd Histogen Inc RepliCel Life Sciences Inc RiverTown Therapeutics Inc Samumed LLC Sucampo Pharmaceuticals Inc SWITCH Biotech LLC